These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2076202)

  • 41. Isolation of [hydroxyproline3]Lysyl-bradykinin formed by kallikrein from human plasma protein.
    Sasaguri M; Ikeda M; Ideishi M; Arakawa K
    Adv Exp Med Biol; 1989; 247A():539-44. PubMed ID: 2603820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Degradation of Ile-Ser-Bradykinin by enzymes in human serum and ascites.
    Rehbock J; Wunderer G
    Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):1081-3. PubMed ID: 2009076
    [No Abstract]   [Full Text] [Related]  

  • 43. Measurements of urinary kinins by HPLC-radioimmunoassay.
    Fejes-Tóth G; Náray-Fejes-Tóth A; Frölich JC
    Clin Chim Acta; 1984 Jun; 140(1):21-9. PubMed ID: 6564947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Apolipoprotein A1 and apolipoprotein B in pleural effusions].
    García Pachón E; Llorca Escuin IL
    Rev Clin Esp; 2005 Aug; 205(8):363-6. PubMed ID: 16143082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a radioimmunoassay for [DES-ARG9]-bradykinin.
    Odya CE; Moreland P; Stewart JM; Barabe J; Regoli DC
    Biochem Pharmacol; 1983 Jan; 32(2):337-42. PubMed ID: 6870961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
    Zebrowski BK; Yano S; Liu W; Shaheen RM; Hicklin DJ; Putnam JB; Ellis LM
    Clin Cancer Res; 1999 Nov; 5(11):3364-8. PubMed ID: 10589746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of human and rat tissue kallikreins by peptide analog antagonists of bradykinin.
    Spragg J; Vavrek RJ; Stewart JM
    Adv Exp Med Biol; 1989; 247B():277-81. PubMed ID: 2610073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice.
    Gabra BH; Sirois P
    Eur J Pharmacol; 2002 Dec; 457(2-3):115-24. PubMed ID: 12464357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
    Qian XP; Liu BR; Jiang M; Hu J; Yu LX; Wang LF; Hu WJ; Zou ZY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):457-60. PubMed ID: 21875488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
    Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
    Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection and quantitation of fluorescamine-labeled bradykinin, its analogues and metabolites using high-performance liquid chromatography.
    Narayanan TK; Greenbaum LM
    J Chromatogr; 1984 Mar; 306():109-16. PubMed ID: 6143761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma.
    Shima C; Majima M; Katori M
    Jpn J Pharmacol; 1992 Oct; 60(2):111-9. PubMed ID: 1479739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced passage of alpha 2-macroglobulin into malignant serous effusions and diminished antifibrinolytic potential of the fluid.
    Cucuianu M; Cristea A; Marcu A; Riviş O
    Med Interne; 1990; 28(3):209-18. PubMed ID: 1709293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolation of brain endopeptidases: influence of size and sequence of substrates structurally related to bradykinin.
    Oliveira EB; Martins AR; Camargo AC
    Biochemistry; 1976 May; 15(9):1967-74. PubMed ID: 5120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxyprolyl3-bradykinin in high molecular mass kininogen. Presence in human and monkey kininogens, but not in kininogens from bovine, rat, rabbit, guinea pig and mouse plasmas.
    Enjyoji K; Kato H
    FEBS Lett; 1988 Sep; 238(1):1-4. PubMed ID: 3139453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Purification, structural characterization, and myotropic activity of a peptide related to des-Arg(9)-bradykinin from an elasmobranch fish, the little skate, Leucoraja erinacea.
    Anderson WG; Leprince J; Conlon JM
    Peptides; 2008 Aug; 29(8):1280-6. PubMed ID: 18502540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Action and metabolism of des(Arg)kinins in mesenteric arteries.
    Churchill L; McGiff JC; Ward PE
    Adv Exp Med Biol; 1986; 198 Pt A():571-5. PubMed ID: 3812095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
    J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.